A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults

PURPOSE: In this dose-finding Phase II study (NCT00621322), we evaluated the safety and immunogenicity of different formulations of the candidate tuberculosis vaccine containing the M72 antigen (10/20/40 μg doses) and the liposome-based AS01 Adjuvant System. We aimed to select the lowest-dose combin...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Montoya, Jaime, Solon, Juan Antonio, Cunanan, Soledad Rosanna C., Acosta, Luz, Bollaerts, Anne, Moris, Philippe, Janssens, Michel, Jongert, Erik, Demoitié, Marie-Ange, Mettens, Pascal, Gatchalian, Salvacion, Vinals, Carlota, Cohen, Joe, Ofori-Anyinam, Opokua
Формат: Artigo
Язык:Inglês
Опубликовано: Springer US 2013
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3825318/
https://ncbi.nlm.nih.gov/pubmed/24142232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-013-9949-3
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы